In a preclinical study using mouse model, it was shown that check point inhibitors like CTLA-4 and PD-1 activate CD103+ DCs and increase IL-12 secretion by them, leading to an increase in the anti-tumor immune response (58). Here, CTLA4 is linked to neoplasm.